Business Wire Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study
January 23, 2020
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Freenome, a privately-held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection through a routine blood draw, is presenting data from their prospective, multi-center clinical study AI-EMERGE®. The colorectal cancer (CRC) study will be featured at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) on Saturday, January 25th in San Francisco. “We’re delighted to present results from the first prospective clinical study with our multiomics blood test that achieved high sensitivity and specificity in early-stage CRC,” said Gabriel Otte, Chief Executive Officer of Freenome. “This represents a significant step forward in our efforts to bring an effective early detection test to as many people as possible.”
Full news article can be found here.